Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
NCT: NCT06483100 · RECRUITING
Brief Summary
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Frequently Asked Questions
What is Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance?
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance is a clinical trial registered under NCT06483100. Current status: RECRUITING.
What is the status of NCT06483100?
The current status of NCT06483100 (Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance) is: RECRUITING.
When did Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance start?
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance started on 2024-12-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.